SEC Company Response from Larimar Therapeutics, Inc. (LRMR) (CIK 0001374690) (LRMR) — Aug 31, 2020
Larimar Therapeutics, Inc. (LRMR) (CIK 0001374690)
Date: Aug. 31, 2020 · CIK: 0001374690 · Accession: 0001193125-20-236337
AI Filing Summary & Sentiment
File numbers found in text: 333-246370
Show Raw Text
CORRESP 1 filename1.htm CORRESP Larimar Therapeutics, Inc. Three Bala Plaza East, Suite 506 Bala Cynwyd, Pennsylvania 19004 August 31, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7553 Re: Larimar Therapeutics, Inc. Registration Statement on Form S-3 Filed August 14, 2020 (File No. 333-246370) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Larimar Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-246370) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:01 PM, Eastern Time, on September 1, 2020, or as soon thereafter as is practicable. Please contact Rachael M. Bushey, Esq. of Troutman Pepper Hamilton Sanders LLP, counsel to the Company, at (215) 981-4331 to provide notice of effectiveness, or if you have any questions or comments concerning this request. [Remainder of the page intentionally left blank] Very truly yours, LARIMAR THERAPEUTICS, INC. By: /s/ Carole Ben-Maimon Name: Carole Ben-Maimon, M.D. Title: President and Chief Executive Officer